The success of its corona vaccine has brought the Mainz company Biontech a huge leap in sales and profits.
As the company announced on Monday, net profit rose to just under 2.8 billion euros in the second quarter of 2021 after a loss of 88.3 million euros in the same period of the previous year.
For the first six months of this year, the surplus amounted to a good 3.9 billion euros after a loss of almost 142 million euros in the previous year.
Sales in the quarter ended June 30th were estimated at around 5.3 billion euros after 41.7 million euros in the previous year.
For the first half of the year there was a total turnover of almost 7.4 billion euros after 69 million euros in the same period of the previous year.
The company's success is also reflected in the stock market.
The paper, which has been listed on the US technology exchange Nasdaq since October 2019, has rushed from record to record in the past few weeks.
On Tuesday, the price rose to $ 433.90 - Biontech was at times worth more than $ 100 billion.
By Friday the course crumbled again a little.
At 389 dollars, however, it was still around 1200 percent above the level at the end of January 2020, before the corona pandemic hit the world.
Since the IPO in autumn 2019, the price has increased by around 2500 percent. Biontech is currently worth around 94 billion dollars or the equivalent of almost 80 billion euros on the stock exchange. Due to the rapid rise in the share price, the brothers Andreas and Thomas Strüngmann, who hold almost half of the shares, are now among the richest Germans. The 17 percent package from company founder and boss Ugur Sahin is worth almost 14 billion euros. According to a list by the Bloomberg news agency, he is also one of the ten richest Germans.